Gemcitabine (G) plus cisplatin (C) is a highly active regimen in first-line treatment of metastatic breast cancer (MBC): Results of a multicenter phase II trial

被引：0
|
作者：
Fuentes, H
Calderillo, G
Alexander, F
Ramirez, M
Avila, E
Perez, L
Aguirre, C
机构：
[1] Inst Nacl Cancerol, SSA, Mexico City, DF, Mexico
[2] Hosp Gen Occidente Seguro Social, SSA, Oncol Serv, Guadalajara, Jalisco, Mexico
[3] IMSS, Unidad Morelos 1, Cuernavaca, Morelos, Mexico
[4] Ctr Med Potosi, Oncol & Radiotherapy Serv, San Luis Potosi, Mexico
[5] Clin ISSSTE, Oncol Serv, Ensenada, Baja California, Mexico
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
10.1016/S0959-8049(02)80216-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
130
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [31] Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer
    Hoelzer, K. L.
    Brufsky, A.
    Hainsworth, J.
    Beck, J. T.
    Whorf, R.
    Keaton, M.
    Kroener, J.
    Krill-Jackson, E.
    Hu, S.
    Bromund, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary Tract
    Karachaliou, Niki
    Polyzos, Aris
    Kentepozidis, Nikolaos
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Vardakis, Nikolaos
    Kalykaki, Antonia
    Milaki, Georgia
    Georgoulias, Vassilis
    Androulakis, Nikolaos
    ONCOLOGY, 2010, 78 (5-6) : 356 - 360
  • [33] Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: Results of a phase II study
    Klaassen, U
    Wilke, H
    Muller, C
    Borquez, D
    Harstrick, A
    Seeber, S
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 58 - 60
  • [34] Final results of gemcitabine (G) and epirubicin (E) phase II trial in metastatic breast cancer (MBC) patients (pts).
    Fumoleau, P
    Viens, P
    Dieras, V
    Pujade-Lauraine, E
    Serin, D
    Petit, T
    Espie, M
    Kayitalire, L
    Robert, C
    Pouillart, P
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S90 - S90
  • [35] Navelbine (N) capecitabine (C) combination (Navcap); the new first line chemotherapy regimen for metastatic breast cancer (MBC): results of phase II trial.
    Ghosn, M
    Kattan, J
    Farhat, F
    Gasmi, J
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S133 - S133
  • [36] Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first line treatment of metastatic breast cancer: Results of a multicenter phase II study
    Riccardi, A
    Brugnatelli, S
    Danova, M
    Giordano, M
    Pugliese, P
    Luchena, G
    Grasso, D
    Trotti, G
    Berte, R
    Pansini, G
    Tinelli, C
    TUMORI, 2006, 92 (01) : 6 - 12
  • [37] Phase II study of gemcitabine plus cisplatin in metastatic breast cancer
    Fuentes, Homero
    Calderillo, German
    Alexander, Francisco
    Ramirez, Marcelino
    Avila, Enrique
    Perez, Leonel
    Aguirre, Guillermo
    Onate-Ocana, Luis F.
    Gallardo, Dolores
    Otero, Jorge
    ANTI-CANCER DRUGS, 2006, 17 (05) : 565 - 570
  • [38] A prospective, multicenter, phase II trial of albumin-paclitaxel plus cisplatin versus gemcitabine plus cisplatin in first-line treatment of advanced biliary tract tumors.
    Yang, Xiao
    Zhuang, Liang
    Dai, Yuhong
    Qiu, Hong
    Yuan, Xianglin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Gemcitabine (G) plus capecitabine (C) in previously treated metastatic breast cancer (MBC) patients.: Final results from a phase II GOTI trial.
    Pérez-Manga, G
    López-Criado, P
    Méndez, M
    Quiben, R
    Palomero, I
    Sancho, JF
    Belón, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S205 - S206
  • [40] Gemcitabine and cisplatin combination chemotherapy as first-line treatment in patients with metastatic breast cancer.
    Alauddin, Z
    Shaharyar, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 56S - 56S
12345